ANVS — Annovis Bio Inc
NYSE · Healthcare · Biotechnology
$1.71
+$0.02 (+1.18%)
Annovis Bio Inc (ANVS) is a biotechnology company listed on NYSE. It is led by Maria L. Maccecchini Ph.D., based in 101 Lindenwood Drive, Malvern, PA, United States, 19355, with about 7 employees. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Latest reported ANVS revenue for 2025-09-30 was $0. Net income was -$19.0M. ANVS currently screens at market cap $80.4M.
Use this ANVS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ANVS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ANVS SEC filings page. Lician reads the product cache first so this HTML stays unique to Annovis Bio Inc even when a live quote feed is slow.
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
ANVS Key Statistics
Market Cap
$80.40M
Volume
560,120
Previous Close
$1.75
Day Range
$1.76 – $1.82
EPS
-$2.31
Revenue
$0.00
Net Income
-$24.59M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
7
ANVS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$24.59M | -$56.20M | -$25.33M |
| EPS (Diluted) | -$2.31 | -$6.23 | -$3.10 |
Total Assets
$13.93M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$10.55M
Operating Cash Flow
-$21.89M
Free Cash Flow
$0.00
Annovis Bio Inc Company Information
- Founder, Acting CFO, CEO, President & Executive Director
- Maria L. Maccecchini Ph.D.
- Headquarters
- 101 Lindenwood Drive, Malvern, PA, United States, 19355
- Website
- www.annovisbio.com
- Phone
- 484 875 3192
- IPO / Founded
- 2010-02-12
- Sector
- Healthcare
- Industry
- Biotechnology